Inclusion Criteria:

          -  Patient with a TP53wt locally advanced or metastatic solid malignancy and with
             measurable or non-measurable (but evaluable) disease as determined by RECIST 1.1
             criteria.

          -  Patients with the TP53wt hematological tumors (AML, ALL, HR-MDS) who have failed prior
             therapies or who are considered inappropriate candidates for standard induction
             therapy.

        Other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  Prior treatment with compounds with the same mode of action

          -  Subjects with significant or uncontrolled cardiovascular disease

          -  History of thromboembolic or cerebrovascular events within the last 6 months,
             including transient ischemic attack, cerebrovascular accident, deep vein thrombosis,
             or pulmonary embolism

          -  Previous and concomitant therapy that precludes enrollment, as defined in the protocol

          -  Known Human Immunodeficiency Virus (HIV) infection and/or active Hepatitis B or
             Hepatitis C infection

          -  Patients who have undergone major surgery within the 2 weeks prior to starting study
             treatment or who have not fully recovered from previous surgery

          -  Women of child-bearing potential, unless they are using highly effective methods of
             contraception during dosing and for 2 weeks after study drug discontinuation

          -  Pregnant or nursing women

        Other protocol-defined inclusion/exclusion criteria may apply